Swiss pharmaceutical giant Roche Holding AG’s (RHHBY.PK: News ) unit Genentech Monday stated that its investigational drug vismodegib showed positive results in a pivotal phase II study in people with basal cell carcinoma, an advanced form of skin cancer.
